Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer

Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data evaluating the utilization and challenges to deliver durvalumab consolidation in the real world. We assessed the use of consolidative durvalu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Radiother Oncol
Main Authors: Shaverdian, Narek, Offin, Michael D., Rimner, Andreas, Shepherd, Annemarie F., Wu, Abraham J., Rudin, Charles M., Hellmann, Matthew D., Chaft, Jamie E., Gomez, Daniel R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523024/
https://ncbi.nlm.nih.gov/pubmed/31786421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2019.11.015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados